Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Thalassemia Majors (Beta-Thalassemia Major)

Tundra lists 5 Thalassemia Majors (Beta-Thalassemia Major) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT07782931

Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With Deferoxamine

This research study was an experimental, randomized, controlled clinical trial to evaluate the safety and efficacy of coded Unani formulation Irochel for the management of IOL due to repetitive blood transfusion in comparison with DFO in already diagnosed 132 transfusion-dependent thalassemia patients of both genders of 10 years to 16 years of age. The study was conducted at Hamdard Matab, Araam Bagh, where patients came from multiple thalassemia centers such as the Hussaini Blood Bank, National Institute of Blood Diseases (NIBD), Fatimid Foundation, Umair Sana Thalassemia Center, Kashif Iqbal Thalassemia Center, and Civil Hospital. The data was collected through the Clinical Record Form (CRF) and then analyzed by SPSS version 23. The study was conducted during the years 2014-2020. The study comprises two phases: 1) Development of Irochel and 2) Clinical Trials. The "Irochel" is a round, disk-shaped, black-colored, bitter, polyherbal formulation of 500 mg (tablet) with a characteristic odor. It consists of different ratios of extracts (hydroethanolic) of six medicinal herbs. The combined effect of these novel herbs was found to be potent in iron chelation and helps to improve the quality of life of thalassemia patients due to their high nutritional values and ethnopharmacological activities and their broad spectrum of therapeutic potential.

Gender: All

Ages: 10 Years - 20 Years

Updated: 2026-08-25

1 state

Iron Overload Due to Repeated Red Blood Cell Transfusions
Thalassemia Majors (Beta-Thalassemia Major)
NOT YET RECRUITING

NCT07509996

Risk Factors Affecting Growth in Thalassemic Children at AUCH

Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.

Gender: All

Ages: 12 Months - 18 Years

Updated: 2026-04-03

Thalassemia Majors (Beta-Thalassemia Major)
NOT YET RECRUITING

NCT07288762

Gonadal Function in Thalassemic Patient

Patient with transfusion depandant beta thalassemia with accumulation of iron in their body affect pituitary gland and gonades lead to impaired their functions .

Gender: MALE

Ages: 10 Years - 18 Years

Updated: 2025-12-17

Thalassemia Majors (Beta-Thalassemia Major)
NOT YET RECRUITING

NCT06980662

The Effect of Laughter Yoga in Beta Thalassaemia Major Patients: a Randomised Controlled Trial

The aim of this study was to evaluate the effects of laughter yoga on Fatigue, Depression-Anxiety-Stress, Sleep quality, Haematological values and Blood transfusion number in Beta Thalassemia Major patients.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2025-05-20

Beta Thalassemia Major
Thalassemia Majors (Beta-Thalassemia Major)
RECRUITING

NCT06734520

Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia

This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.

Gender: All

Ages: 7 Years - 10 Years

Updated: 2024-12-16

1 state

Thalassemia Majors (Beta-Thalassemia Major)
Haplo-identical Donors